Evidence map›Paper›PMID 37398273›Full record

ArticlebioRxiv : the preprint server for biology2023

Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.

Brian J Woo, Ruhollah Moussavi-Baygi, Heather Karner, Mehran Karimzadeh, Kristle Garcia, Tanvi Joshi, Keyi Yin, Albertas Navickas, Luke A Gilbert, Bo Wang and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Brian J WooDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Ruhollah Moussavi-BaygiDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Heather KarnerDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Mehran KarimzadehDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Kristle GarciaDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Tanvi JoshiDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Keyi YinDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Albertas NavickasDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Luke A GilbertDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Bo WangVector Institute, Toronto, ON, Canada.
Hosseinali AsgharianDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
Felix Y FengDepartment of Urology, University of California, San Francisco, San Francisco, California, USA.
Hani GoodarziDepartment of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USUniversity Health Network · CA

Funding

An antisense RNA-mediated regulatory program that drives cancer metastasisR01CA240984 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2019 to 2023
$2.5M
A GENETIC INTERACTION MAP OF THE HUMAN NUCLEUSDP2CA239597 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2018 to 2018
$2.4M
The RNA structural code underlying pathological regulation of RNA splicing in metastasisR01CA244634 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2021 to 2025
$1.8M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NCI NIH HHS DP2 CA239597NCI NIH HHS R01 CA240984NCI NIH HHS R01 CA244634NIH HHS S10 OD028511
6 · The paper itself

Abstract

Large-scale sequencing efforts of thousands of tumor samples have been undertaken to understand the mutational landscape of the coding genome. However, the vast majority of germline and somatic variants occur within non-coding portions of the genome. These genomic regions do not directly encode for specific proteins, but can play key roles in cancer progression, for example by driving aberrant gene expression control. Here, we designed an integrative computational and experimental framework to identify recurrently mutated non-coding regulatory regions that drive tumor progression. Application of this approach to whole-genome sequencing (WGS) data from a large cohort of metastatic castration-resistant prostate cancer (mCRPC) revealed a large set of recurrently mutated regions. We used (i)

Identifiers

PMID37398273
PMCPMC10312451
OpenAlexW4366003799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.